Personal information

Websites & social links

Linkedin

Other IDs

Scopus Author ID: 33067821800

Keywords

Lymphoma, Immunotherapy

Countries

United States

Activities

Collapse all

Employment (7)

Memorial Sloan Kettering Cancer Center: New York, NY, US

2019-07-29 to present | Assistant Attending (Medicine)
Employment
Source: Self-asserted source
Lorenzo Falchi

Memorial Sloan Kettering Cancer Center: New York, NY, US

2019-07-24 to present | Assistant Attending L1 (Lymphoma)
Employment
Source: check_circle
Memorial Sloan Kettering Cancer Center

Columbia University Medical Center: New York, NY, US

2015-07 to 2019-06-30 | Fellow (Medicine, Hematology/Oncology)
Employment
Source: Self-asserted source
Lorenzo Falchi

Yale-New Haven Hospital: New Haven, CT, US

2013-07 to 2015-06 | Resident (Medicine)
Employment
Source: Self-asserted source
Lorenzo Falchi

University of Texas MD Anderson Cancer Center: TX, TX, US

2012-07 to 2013-06 | Clinical Fellow (Leukemia)
Employment
Source: Self-asserted source
Lorenzo Falchi

University of Texas MD Anderson Cancer Center: TX, TX, US

2011-09 to 2012-07 | Postdoctoral Fellow (Leukemia)
Employment
Source: Self-asserted source
Lorenzo Falchi

Università degli Studi di Perugia Facoltà di Medicina e Chirurgia: Perugia, Umbria, IT

2005-11 to 2009-10 | Resident/Fellow (Internal Medicine and Oncologic Sciences)
Employment
Source: Self-asserted source
Lorenzo Falchi

Education and qualifications (1)

Università degli Studi di Perugia Facoltà di Medicina e Chirurgia: Perugia, Umbria, IT

1999-10 to 2005-07 | MD
Education
Source: Self-asserted source
Lorenzo Falchi

Professional activities (4)

American Society of Hematology: Washington, DC, US

Membership
Source: Self-asserted source
Lorenzo Falchi

American Society of Clinical Oncology: Alexandria, VA, US

Membership
Source: Self-asserted source
Lorenzo Falchi

American Medical Association: Chicago, IL, US

Membership
Source: Self-asserted source
Lorenzo Falchi

American Association for Cancer Research: Philadelphia, PA, US

Membership
Source: Self-asserted source
Lorenzo Falchi

Funding (1)

Mosunetuzumab for the treatment of patients with newly diagnosed follicular lymphoma

2022-03-01 to 2025-02-28 | Grant
Lymphoma Research Foundation (New York, US)
GRANT_NUMBER:

903765
Source: check_circle
ProposalCentral

Works (50 of 57)

Items per page:
Page 1 of 2

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood
2024-04-18 | Journal article
DOI: 10.1182/blood.2023022432
Contributors: Jennifer L. Crombie; Tara Graff; Lorenzo Falchi; Yasmin H. Karimi; Rajat Bannerji; Loretta Nastoupil; Catherine Thieblemont; Renata Ursu; Nancy Bartlett; Victoria Nachar et al.
Source: check_circle
Crossref

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532596
Contributors: Lindsey E. Roeker; Tatyana A. Feldman; Jacob D. Soumerai; Victoria Falco; Gail Panton; Colleen Dorsey; Andrew D. Zelenetz; Lorenzo Falchi; Jae H. Park; David J. Straus et al.
Source: check_circle
Crossref

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532596.v1
Contributors: Lindsey E. Roeker; Tatyana A. Feldman; Jacob D. Soumerai; Victoria Falco; Gail Panton; Colleen Dorsey; Andrew D. Zelenetz; Lorenzo Falchi; Jae H. Park; David J. Straus et al.
Source: check_circle
Crossref

Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487868
Contributors: Lindsey E. Roeker; Tatyana A. Feldman; Jacob D. Soumerai; Victoria Falco; Gail Panton; Colleen Dorsey; Andrew D. Zelenetz; Lorenzo Falchi; Jae H. Park; David J. Straus et al.
Source: check_circle
Crossref

Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22487868.v1
Contributors: Lindsey E. Roeker; Tatyana A. Feldman; Jacob D. Soumerai; Victoria Falco; Gail Panton; Colleen Dorsey; Andrew D. Zelenetz; Lorenzo Falchi; Jae H. Park; David J. Straus et al.
Source: check_circle
Crossref

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

Blood
2023-02-02 | Journal article
DOI: 10.1182/blood.2021011994
Contributors: Lorenzo Falchi; Santosha A. Vardhana; Gilles A. Salles
Source: check_circle
Crossref

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Clinical Cancer Research
2022-09-15 | Journal article
DOI: 10.1158/1078-0432.CCR-22-0964
Contributors: Lindsey E. Roeker; Tatyana A. Feldman; Jacob D. Soumerai; Victoria Falco; Gail Panton; Colleen Dorsey; Andrew D. Zelenetz; Lorenzo Falchi; Jae H. Park; David J. Straus et al.
Source: check_circle
Crossref

18FDG‐avid cholesterol granuloma mimicking residual aggressive lymphoma after chemotherapy

eJHaem
2022-02 | Journal article
DOI: 10.1002/jha2.332
Contributors: Lorenzo Falchi; Filiz Sen
Source: check_circle
Crossref

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Blood Cancer Journal
2022-02-10 | Journal article
DOI: 10.1038/s41408-022-00620-w
Contributors: Fushen Sha; Michelle Okwali; Anna Alperovich; Philip C. Caron; Lorenzo Falchi; Audrey Hamilton; Paul A. Hamlin; Steven M. Horwitz; Erel Joffe; Niloufer Khan et al.
Source: check_circle
Crossref

Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation

Leukemia & Lymphoma
2021-10-15 | Journal article
DOI: 10.1080/10428194.2021.1941936
Contributors: Eric Mou; Lorenzo Falchi; Vandana Sundaram; Jeremy S. Abramson; Ronald Balassanian; Sara Beygi; Megan J. Fitzpatrick; Annabel Kate Frank; Srishti Gupta; Oscar Lin et al.
Source: check_circle
Crossref

Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways

Molecular Cancer Therapeutics
2021-08-01 | Journal article
DOI: 10.1158/1535-7163.MCT-20-0377
Contributors: Luigi Scotto; Cristina Kinahan; Eugene Douglass; Changchun Deng; Maryam Safari; Beatrice Casadei; Enrica Marchi; Jennifer K. Lue; Francesca Montanari; Lorenzo Falchi et al.
Source: check_circle
Crossref

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Blood
2021-04-22 | Journal article
DOI: 10.1182/blood.2020009004
Contributors: Lorenzo Falchi; Helen Ma; Sandra Klein; Jennifer K. Lue; Francesca Montanari; Enrica Marchi; Changchun Deng; Hye A. Kim; Aishling Rada; Alice T. Jacob et al.
Source: check_circle
Crossref

Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials

Hematological Oncology
2020 | Journal article
DOI: 10.1002/hon.2705
EID:

2-s2.0-85077894046

Part of ISBN:

10991069 02780232
Contributors: Ma, H.; Cheng, B.; Falchi, L.; Marchi, E.; Sawas, A.; Bhagat, G.; O'Connor, O.A.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier
grade
Preferred source (of 2)‎

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Blood
2019-10-24 | Journal article
DOI: 10.1182/blood.2019001285
Contributors: Owen A. O’Connor; Lorenzo Falchi; Jennifer K. Lue; Enrica Marchi; Cristina Kinahan; Ahmed Sawas; Changchun Deng; Francesca Montanari; Jennifer E. Amengual; Hye A. Kim et al.
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

Journal of geriatric oncology
2019-04-17 | Journal article
DOI: 10.1016/j.jgo.2019.04.002
PMID: 31005650
Source: Self-asserted source
Lorenzo Falchi
grade
Preferred source (of 2)‎

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Blood
2018 | Journal article
DOI: 10.1182/blood-2017-09-806737
EID:

2-s2.0-85041066632
Contributors: Amengual, J.E.; Lichtenstein, R.; Lue, J.; Sawas, A.; Deng, C.; Lichtenstein, E.; Khan, K.; Atkins, L.; Rada, A.; Kim, H.A. et al.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

The Lancet Oncology
2018 | Journal article
DOI: 10.1016/S1470-2045(17)30912-9
EID:

2-s2.0-85038871173
Contributors: O'Connor, O.A.; Lue, J.K.; Sawas, A.; Amengual, J.E.; Deng, C.; Kalac, M.; Falchi, L.; Marchi, E.; Turenne, I.; Lichtenstein, R. et al.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Kit Mutations: New Insights and Diagnostic Value

Immunology and Allergy Clinics of North America
2018 | Journal article
DOI: 10.1016/j.iac.2018.04.005
EID:

2-s2.0-85048296625
Contributors: Falchi, L.; Verstovsek, S.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Polycythemia vera and essential thrombocythemia

Journal of Clinical Outcomes Management
2018 | Journal article
EID:

2-s2.0-85054498760
Contributors: Falchi, L.; Verstovsek, S.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma

Clinical Lymphoma Myeloma and Leukemia
2018-08 | Journal article
DOI: 10.1016/j.clml.2018.05.009
Contributors: Lorenzo Falchi; Alessandra Ferrajoli; Ira Jacobs; Pilar Nava-Parada
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

British Journal of Haematology
2017 | Journal article
DOI: 10.1111/bjh.14443
EID:

2-s2.0-85010902373
Contributors: Falchi, L.; Bose, P.; Newberry, K.J.; Verstovsek, S.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era

Leukemia
2017 | Journal article
DOI: 10.1038/leu.2017.150
EID:

2-s2.0-85028844678
Contributors: Falchi, L.; Kantarjian, H.M.; Verstovsek, S.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies

Current Hematologic Malignancy Reports
2017 | Journal article
DOI: 10.1007/s11899-017-0410-1
EID:

2-s2.0-85027851296
Contributors: Falchi, L.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

Leukemia Research
2017 | Journal article
DOI: 10.1016/j.leukres.2017.03.008
EID:

2-s2.0-85016492956
Contributors: Boddu, P.; Falchi, L.; Hosing, C.; Newberry, K.; Bose, P.; Verstovsek, S.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review

Annals of Hematology
2017 | Journal article
DOI: 10.1007/s00277-017-3099-2
EID:

2-s2.0-85027982445
Contributors: Kc, D.; Falchi, L.; Verstovsek, S.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia.

2016 | Journal article
DOI: 10.4084/mjhid.2016.011
PMID: 26977270
PMC: PMC4771137
Contributors: Falchi L; Baron JM; Orlikowski CA; Ferrajoli A
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Journal of Hematology and Oncology
2016 | Journal article
DOI: 10.1186/s13045-016-0363-1
EID:

2-s2.0-84999029511
Contributors: Falchi, L.; Sawas, A.; Deng, C.; Amengual, J.E.; Colbourn, D.S.; Lichtenstein, E.A.; Khan, K.A.; Schwartz, L.H.; O'Connor, O.A.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment

Managing Myeloproliferative Neoplasms: A Case-Based Approach
2016 | Book
Part of DOI: 10.1017/CBO9781316017852.011
EID:

2-s2.0-85048549129
Contributors: Falchi, L.; Verstovsek, S.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters

Translational Cancer Research
2016-09 | Journal article
DOI: 10.21037/tcr.2016.09.31
Contributors: Lorenzo Falchi; Rita Morales; Marco Ruella
Source: Self-asserted source
Lorenzo Falchi via Crossref Metadata Search
grade
Preferred source (of 2)‎

Severe mechanical hemolysis in a patient with thalassemia minor who had undergone inappropriate splenectomy.

2016-08 | Journal article
DOI: 10.1007/s12185-016-2023-1
PMID: 27206816
Contributors: Falchi L; Grillo LM; Diuguid-Gerber JL; Eisenberger AB; Jurcic JG
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.

2016-06 | Journal article
DOI: 10.1093/annonc/mdw072
PMID: 26912560
Contributors: Falchi L; Vitale C; Keating MJ; Lerner S; Wang X; Elhor Gbito KY; Strom S; Wierda WG; Ferrajoli A
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

2016-05 | Journal article
DOI: 10.1158/1078-0432.ccr-15-2476
PMID: 26733610
Contributors: Vitale C; Falchi L; Ten Hacken E; Gao H; Shaim H; Van Roosbroeck K; Calin G; O'Brien S; Faderl S; Wang X et al.
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.

2016-04 | Journal article
DOI: 10.1002/cncr.29852
PMID: 26716387
Contributors: Falchi L; Verstovsek S; Ravandi-Kashani F; Kantarjian HM
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

British Journal of Haematology
2015 | Journal article
DOI: 10.1111/bjh.13377
EID:

2-s2.0-84942914657
Contributors: Thompson, P.A.; Rozovski, U.; Keating, M.J.; Stingo, F.; Smith, S.C.; Wierda, W.G.; Falchi, L.; O'Brien, S.M.; Estrov, Z.; Burger, J.A. et al.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

Eosinophilia in Hematologic Disorders.

2015-08 | Journal article
DOI: 10.1016/j.iac.2015.04.004
PMID: 26209894
PMC: PMC4515577
Contributors: Falchi L; Verstovsek S
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

New Therapeutic Approaches in Polycythemia Vera.

2015-06 | Journal article
DOI: 10.1016/j.clml.2015.02.013
PMID: 26297275
PMC: PMC4548804
Contributors: Falchi L; Newberry KJ; Verstovsek S
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.

2014-10 | Journal article
DOI: 10.1038/leu.2014.168
PMID: 24854988
PMC: PMC4824944
Contributors: Falchi L; Mehrotra M; Newberry KJ; Lyle LM; Lu G; Patel KP; Luthra R; Popat U; Verstovsek S
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Bullet 'manicure': does lead prevent hydroxyurea-induced cutaneous toxicity?

2014-05 | Journal article
DOI: 10.1093/jjco/hyu011
PMID: 24782486
Contributors: Falchi L; Quintás-Cardama A
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.

2014-05 | Journal article
DOI: 10.1182/blood-2013-11-536169
PMID: 24615780
PMC: PMC4123418
Contributors: Falchi L; Keating MJ; Marom EM; Truong MT; Schlette EJ; Sargent RL; Trinh L; Wang X; Smith SC; Jain N et al.
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.

2013-12 | Journal article
DOI: 10.1002/ajh.23560
PMID: 23913852
PMC: PMC3849405
Contributors: Falchi L; Kantarjian HM; Wang X; Verma D; Quintás-Cardama A; O'Brien S; Jabbour EJ; Ravandi-Kashani F; Borthakur G; Garcia-Manero G et al.
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.

2013-09 | Journal article
DOI: 10.1002/cncr.28030
PMID: 24022787
PMC: PMC4394603
Contributors: Falchi L; Keating MJ; Wang X; Coombs CC; Lanasa MC; Strom S; Wierda WG; Ferrajoli A
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas.

2012 | Journal article
DOI: 10.1155/2012/523842
PMID: 22761620
PMC: PMC3384930
Contributors: Gunnellini M; Falchi L
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.

2012-12 | Journal article
DOI: 10.1016/j.clineuro.2012.03.038
PMID: 22516417
Contributors: Falchi L; Gunnellini M; Ferranti L; Liberati AM
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Chronic lymphocytic leukemia in African Americans.

2012-11 | Journal article
DOI: 10.3109/10428194.2012.698276
PMID: 22646816
Contributors: Coombs CC; Falchi L; Weinberg JB; Ferrajoli A; Lanasa MC
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans.

2012-08 | Journal article
DOI: 10.1182/blood-2012-02-408799
PMID: 22745306
PMC: PMC3429309
Contributors: Coombs CC; Rassenti LZ; Falchi L; Slager SL; Strom SS; Ferrajoli A; Weinberg JB; Kipps TJ; Lanasa MC
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.

2012-02 | Journal article
DOI: 10.1111/j.1365-2141.2011.08965.x
PMID: 22150204
Contributors: Cortelezzi A; Gritti G; Laurenti L; Cuneo A; Ciolli S; Di Renzo N; Musto P; Mauro FR; Cascavilla N; Falchi L et al.
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

The Value of Molecular Response in Chronic Myeloid Leukemia: The Present and the Future

Myeloid Leukemia - Clinical Diagnosis and Treatment
2012-01-05 | Other
DOI: 10.5772/26119
Contributors: Lorenzo Falchi; Viviana Appolloni; Lucia Ferranti; Anna Marina
Source: Self-asserted source
Lorenzo Falchi via Crossref Metadata Search

Maesopsin 4-O-β-<inf>D</inf>-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia

Journal of Chemotherapy
2011 | Journal article
DOI: 10.1179/joc.2011.23.3.150
EID:

2-s2.0-80052741094
Contributors: Pozzesi, N.; Pierangeli, S.; Vacca, C.; Falchi, L.; Pettorossi, V.; Martelli, M.P.; Thuy, T.T.; Ninh, P.T.; Liberati, A.M.; Riccardi, C. et al.
Source: Self-asserted source
Lorenzo Falchi via Scopus - Elsevier

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.

2011-12 | Journal article
DOI: 10.1002/ajh.22171
PMID: 21953617
Contributors: Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G et al.
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
grade
Preferred source (of 2)‎

Maesopsin 4-O-beta-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia.

2011-06 | Journal article
PMID: 21742584
Contributors: Pozzesi N; Pierangeli S; Vacca C; Falchi L; Pettorossi V; Martelli MP; Thuy TT; Ninh PT; Liberati AM; Riccardi C et al.
Source: Self-asserted source
Lorenzo Falchi via Europe PubMed Central
Items per page:
Page 1 of 2

Peer review (5 reviews for 2 publications/grants)

Review activity for Journal for immunotherapy of cancer. (4)
Review activity for The oncologist. (1)
How many people are using ORCID?